Dibunic Acid

Summary

Dibunic Acid (CHEMBL1865134) is an approved small-molecule antitussive (ATC R05DB16); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05DB16
• Indications: 1 condition
• Chemistry: 320.4 Da · C18H24O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1865134
Name	Dibunic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	84746
ChEBI	CHEBI:146215
ATC	R05DB16
Molecular formula	C18H24O3S
Molecular weight	320.4
InChIKey	WBEBQCINXJDZCX-UHFFFAOYSA-N

SMILES: CC(C)(C)C1=CC2=C(C=C1)C(=C(C=C2)C(C)(C)C)S(=O)(=O)O

IUPAC name: 2,6-ditert-butylnaphthalene-1-sulfonic acid

ChEBI definition: A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid which is substituted by tert-butyl groups at positions 2 and 6.

Pharmacological roles (ChEBI): antitussive.

Also known as: Dibunate, Dibunato, SID50125928, SID124893716, DIBUNIC ACID

Parent form; salt/anhydrous children: CHEMBL2107554

Patent coverage: 78 distinct patent families (313 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 309 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).